JAK2 and myeloproliferative disorder: Therefore, current efforts are directed towards additional targets involved in the dysregulated proliferation of MPN cells and/or novel therapeutic options with the hope to maximize anticancer efficacy and/or improve the tolerability profile of available JAK2 inhibitors.